`
`LUPIN EX. 1001
`Lupin v. iCeutica
`US Patent No. 9,017,721
`
`
`
`US 9,017,721 B2
`Page 2
`
`(2006.01)
`(2006.01)
`(2006.01)
`
`an mum.
`A61K 9/14
`A61K 9/51
`A61K 9/00
`53 usCL
`CPC .............. .. A61K 9/145 (2013.01); A61K 9/146
`(2013.01); A61K 9/5115 (2013.01); A61K
`9/5123 (2013.01); A61K 9/513 (2013.01);
`A61K 9/0087(2013.01); A61K 9/14 (2013.01);
`A61K31/196 (2013.01); A61K 9/4825
`(2013.01)
`
`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`5,518,187 A
`6,592,903 B2
`6,634,576 B2
`7,101,576 B2
`2004/0022846 A1
`2006/0287346 A1
`2009/0028948 A1
`2010/0092563 A1
`2012/0135047 A1
`2013/0209569 A1
`
`5/1996 Bruno et al.
`7/2003 Ryde et al.
`10/2003 Verhoff et al.
`9/2006 Hovey et al.
`2/2004 Depui et al.
`12/2006 Van Schie
`1/2009 Payne et al.
`4/2010 Raffaele et al.
`5/2012 Dodd et al.
`8/2013 Dodd et al.
`
`FOREIGN PATENT DOCUMENTS
`
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`
`11/2006
`W0 2006/116596
`12/2006
`W0 2006/133954
`W0 2006133954 A2 * 12/2006
`W0 2007/070851
`6/2007
`W0 2007/070852
`6/2007
`W0 2008/000042
`1/2008
`W0 2008000042 A1 *
`1/2008
`
`OTHER PUBLICATIONS
`
`Office Action in corresponding Colombia Patent Application No.
`11-160596, dated Dec. 23, 2013; pp. 1-10.
`Voltaren Package Insert Label and Instructions, Voltaren Gel,
`Novartis Consumer Health, Inc., pp. 1-23 (2009).
`P. Geharmo et al., “Lowest Effective Single Dose of Diclofenac for
`Antipyretic andAnalgesic Effects in Acute Febrile Sore Throat,” Clin
`Drug Invest 2003; 23 (4) 263-271.
`Jenkins and Seligrnan, “Analysis and recommendations for Agency
`action regarding non-steroidal anti-inflammatory drugs and cardio-
`vascular risk,” Center for Drug Evaluation and Research, pp. 1-19
`(2005).
`Liversidge & Conzentino, “Drug particle size reduction for decreas-
`ing gastric irritancy and enhancing absorption of naproxen in rats,”
`International Journal of Pharmaceutics 125 (1995) 309-313.
`Nicholas Moore, “Diclofenac Potassium l2.5mg Tablets for Mild to
`Moderate Pain and Fever, A Review of Its Pharmacology, Clinical
`Efficacy and Safety,” Clin Drug Invest 2007; 27(3): 163-195.
`Sonoda et al., “Improvement of Dissolution Property of Poorly
`Water-Soluble Drug by Novel Dry Coating Method Using Planetary
`Ball Mill,” Chem. Pharm. Bull 56(9) 1243-1247 (2008).
`Vogt et al., “Cogrinding enhances the oral bioavailability of EMD
`57033, a poorly water soluble drug, in dogs,” European Journal of
`Pharmaceutics and Biopharmaceutics 68 (2008) 338-345.
`Vogt et al., “Dissolution enhancement of fenofibrate by microniza-
`tion, cogrinding and srpay-drying: Comparison with commercial
`preparations,”
`European
`Journal
`of
`Pharmaceutics
`and
`Biopharmaceutics 68 (2008) 283-288.
`B. Chuasuwan et al., “Biowaiver Monographs for Immediate Release
`Solid 0ral Dosage Forms: Diclofenac Sodium and Diclofenac Potas-
`sium,” Journal ofPharmaceutical Sciences, 98(4): 1206-1219 (2009).
`Notice of Paragraph IV Certification Regarding NDA 20-4592 Letter
`dated Nov. 24, 2014, pp. 1-42.
`
`* cited by examiner
`
`Page 2
`
`Page 2
`
`
`
`U.S. Patent
`
`Apr. 23, 2015
`
`Sheet 1 0120
`
`US 9,017,721 B2
`
`S
`
`<F9:9“.
`
`Page 3
`
`H...\)O0uW
`
` oA..IA.U.«WD...D:
`
`
`
` EEEH5mmuanEEEE8aEEEEE%0.nwI
`Nv
`<1-
`l.U|'10'L>%l\(")L(')(\ll\LD(")CDLO<")
`ooooup
`rxoocmououcnoooooolx
`<0
`O7
`LO
`07
`U’)
`LO
`mwwaaaaa
`O)
`l\
`l\
`‘D
`00
`VI‘
`©
`C’)
`I\
`<l'
`'
`“"1 09 0> %EEZZEEEE
`m
`N\.
`'
`0
`LD
`l\
`O’)
`<l'<l'<l'
`<l'<l'<l'
`W‘ 03 0> /oHE
`
`N k
`
`l\
`
`C")
`
`mm33_to
`
`0
`
`NawaveonFPomg8-IIIE5N
`
`O
`
`§EII'!H%1.o
`EQEIIIEEE12m
`
`EEIIIIE8:oEN.oN
`
`EEIIIEE8
`
`E&EI"Eaaw83Nmemo8Fmodmoma1115;.-Ia1
`
`EEIIIII
`
`EEIIIIEma
`
`EEIIIEEma
`
`EEI'I!§ma2
`
`V!‘
`
`VI:
`
`00'
`
`0L
`
`O<_
`
`l
`
`_l
`
`_l
`
`(D
`<
`N
`IIIIIIQQEIIQII
`C C)
`C)
`LO
`x
`". ""
`CD.to
`'II
`$<1’
`(6) ssew
`0.<1-
`.oo
`‘.oo
`".
`Ea
`E.»
`co
`0<_I
`2%2EEE%%II
`E’
`IIIII—IIIII—IIIII
`
`
`
`HQIIIEEEm5EIIIII5
`
`Ealllaa5
`
`Ealllaa12
`
`oT
`
`o"
`
`cI
`
`O00
`<E<E<E
`_l
`_l_l
`
`wr1(9'0)G
`
`(
`
`SU|I.U)6I.U|J_
`
`.%wN%wMmmM)M)
`
`61mw
`
`ewe
`
`C\](\]C\l
`
`LD
`
`<|'FF\—0).
`
`
`\—\—\—\—\— \—\—\—\—\—\—\—\—(\](\|
`oo
`NN
`
`0 x
`
`—oooc>—‘—N.
`
`QZ
`
`DZ
`
`0Z
`
`oN DZ
`
`C C)
`N
`.
`N 3
`
`oNT DZ
`
`oN\
`
`- DZ
`
`DD
`Q Q
`DD
`D
`2
`DDQ
`2
`ZZ
`Z Z
`ZZ
`Z
`ZZQ
`EEIHEEE
`
`(6) seem
`
`
`
`
`
`
`
`®N_m®_O_tmn_EfiomtzmEfiomtsm.X_.£m_>_>._mE_._n__m__BmE®>_u_Q<
`
`
`
`
`
`
`
`Page 3
`
`
`
`U.S. Patent
`
`Apr. 23, 2015
`
`Sheet 2 0120
`
`US 9,017,721 B2
`
`LUH 0'3 > 0/0
`
`on
`Ix
`
`cs)
`Ix
`
`03 m 0')
`Ix
`Ix
`oo
`
`oo
`Ix
`
`Ix
`co
`Lo N
`
`oo
`co
`
`oo
`<r
`
`Ix
`co
`\— us
`o Ix o Ix
`
`03
`In
`
`u.|I'1()'L>°/0
`
`(\lwx—C\lQDOLOU)
`c»-.—ooIx
`o3N
`x—mc$>O3cDNlxLOIx
`lxG)L0(\l
`wrm
`EEEEEQ
`MMMEEEEEEEE
`EEEEEHEE
`Mflflflfifififlflfifi
`EEEEEHEE
`LD
`C“)
`O’)
`CO
`_
`®
`\—
`O0
`no
`Ix
`o c»
`Ix
`o Ix
`CD
`uJr1(g0)c|
`Ix
`,\
`“.
`.
`.
`. F.
`.
`0?
`F.
`oo 0.
`1- V.
`0! N.
`F.
`°'>.
`C‘!
`*.
`<9
`\— o o o o N o o o as o o o o o co N ‘— o
`o
`co co
`co
`0')
`co N NN x—
`x— N N N N N N N N N
`WMIIIIIIIIIIIIIIIIIII
`
`.
`
`ParticleSize
`
`(V
`3N:4-4
`U4-4
`
`C(
`
`8‘C:5
`(/3
`
`
`
`
`
`ActivematerialPrimaryMatrixSurfactant#1
`
`
`
`
`
`<|' ® N N C’)
`
`("DC")
`
`LO
`
`0]
`
`(\l
`
`(V
`
`(\l
`
`(\I
`
`(V
`
`(\I
`
`(V)
`
`(V)
`
`IWMHIIHEIEEEIIQIEIIIII
`LO
`IIIIIIEIIIII 2
`euJeN U’
`U)
`(D
`
`g (DEL’ 3 E
`8
`8
`Figure
`O. O. O O O.
`.5663
`IEII
`
`» Z§°°°°°ZEIéHEHIIeaII 1 E 5 2 5 1 ;
`
`
`IIWMIIIIIIIIIIIIIIIIIII
`01Q
`'\—'c\i<\i<\i\—'\—'\—'<r'¢'\—'.—'\—'\—'\_"—'\—'\—‘—II
`
`i
`
`CV
`
`CV
`
`CV
`
`(V
`
`C"? CO ("3
`
`Q‘
`
`VI‘
`
`('3
`
`("3
`
`C")
`
`C")
`
`0')
`
`('3
`
`CO
`
`(V
`
`Page 4
`
`Page 4
`
`
`
`U.S. Patent
`
`Apr. 28,2015
`
`Sheet 3 of 20
`
`US 9,017,721 B2
`
`
`
`) P(% BM
`
`$55!
`@555 3
`mama
`E55 0 g
`C’)
`wnmom m
`0' 0'
`
`II
`
`Figure1C
`
`ParticleSize
`
`(\l
`:11:
`‘E(U4-4
`8'1::3
`ca
`
`Surfactant#1
`
`Page5
`
`Page 5
`
`
`
`U.S. Patent
`
`Apr. 23, 2015
`
`Sheet 4 0120
`
`US 9,017,721 B2
`
`suoneue
`
`IQEEEEEEEIIIEEEQEEI
`
`
`O OEENEEN
`
`IQEQEEEQIIE2.553%
`
`. .o,.m'<._EE11IIEEWE
`
`
`m.m'u<._fig
`
`QQQQQQQ
`
`F
`
`FF
`
`IIQEEEEEIIIEEma2ana8.088Emamom_N
`IEEQEEEEEIIIEEEEEEIQIEQQEEQEEIIIEEEQEEIQ
`
`.
`
`ow
`
`av
`
`<- <[04“
`EEEEE
`
`F._
`_1._
`>>
`
`:5
`
`av
`
`_>._
`
`_>._
`
`:5
`
`Page 6
`
`_1QEEEEEH1..oEIII!EEEE.mEIQlEEIQEEEQEEIIIEEEEEEIQIEE
`
`l\E
`l\®<l'
`NCOG)
`CDOOC\l
`C)
`C’)
`
`EL
`
`O®l\
`C’)<l'\—
`
`mono8Swedaa<._.amug
`
`Nome3wow0<._onmo_o
`
`(‘O
`
`IIT
`
`_3§..EII'lIIQ!ON
`
`AI‘EEEEE€QIIIIIIElEQQ!EIIEEEEEEONIIIIIIEEEQQEEIIQEQEEEQIIIIIIQIEQQIE
`
`
`
`
`
`
`
`%o_WN”oW“NM%W.>>mm.eBee.WswMwMsM.Wnu..mwMS9MeMSMnuC..n1/mwmmmwmw
`
`ww
`
`.n.nw.z\/\I‘r\
`
`
`
`
`
`
`
`®N_mm_o_tmn_(\EfiomtzmEfiomtzwX_bm_>_\Cm_.C__n__m__$mE®>=O<
`
`
`
`
`
`
`
`Page 6
`
`
`
`U.S. Patent
`
`Apr. 28,2015
`
`Sheet 5 of 20
`
`US 9,017,721 B2
`
`suoneue/\
`
`‘ fl‘
`
`<l'
`
`<|' F F F F F F F F F F F F F F F F
`
`LUH
`
`0':
`c)
`<I-
`oo
`oo
`on w
`(°/o)F-“|3!A u—
`oo
`oo
`\— Ix
`uu
`<r
`©
`Ix
`Ix
`Lo
`co
`Ix
`co
`oo
`<i-
`Lo
`Ix m co
`Ix
`o
`o
`o
`o
`oo
`oo
`E Ix
`\—
`on
`x—
`x—
`Ix
`\— cn
`c» G)
`co
`to
`Ix
`Ix
`to o <r o Ix
`' >° o Lo o
`0')
`0')
`co
`an
`‘-10
`LU|'10'L>°/oC")<l'U)OONN81-8
`Ix
`<.o<\icv:oIx
`CD®®<rLO©x—LOx— ooIx
`oo
`mco<rc~o
`BE
`EEEE
`
`Ix
`L0
`
`E $
`
`CD
`('3
`®
`0)
`<l' V V 00
`® (‘'3
`00
`(D
`l\
`07
`<1-ow
`8
`uJr1(g'())c|LoLo®<\iIxIxN<I-N<rooc\1Lo<o
`©.‘—.¢\!‘—.<\!°‘!*.<\!‘—.*.“.<\!*.*....<'?¢0.
`OOOFOOOOOOOOOOOOOFF
`
`.
`NNNNNNNNNNNNNNNN
`LO
`U)
`LO
`IEIIIIIII
`LO
`LO
`N N
`
`o o o
`
`O o
`
`ParticleSize
`
`CV
`333.:
`-I-4
`5-I-4
`
`CC
`
`8'1:3
`(D
`
`N Illlggams
`
`O UJ
`
`(D
`
`D
`
`x I— §
`
`Page 7
`
`Figure1E
`
`I ,
`
`<5) WW3
`G ® 9 9 Q G G G O 9 3 3 ‘D C 3 Q Q G
`C)
`,,,,§§§,,W
`CDCDEDOD.D.D_D—D.D_D.D.D.D.Q_D.D_D.(D
`M/M% °° EA
`I\l\OD®®0O O‘JOO®®O3®CT)CD®
`
`C")CV3C")<l'<l'<l'Vl'VrV|'<l'<I'V'<l'<l'Vl'<l'<l'<l'V'
`
`ewe~°°°22°22 Zo222222°§Z§
`IIIIIIIIIIIIIIIIIII
`
`“
`
`(V
`
`(V
`
`(\I F F F F \_
`
`LO
`
`‘— F F LD F LO F O) F F
`
`‘— \— \— © Q G ® 3 G C Q Q G © Q G 3 Q Q
`_|
`euIeNZZ.EddddLu ddddddddddd
`(DOCDEEEEE EEEEEEEEEEE
`LL
`(D
`—
`x
`°Ne'dweS
`
`.
`
`
`
`ActivematerialPrimaryMatrixSurfactant#1
`
`
`
`
`
`
`
`Page 7
`
`
`
`U.S. Patent
`
`Apr. 28,2015
`
`Sheet 6 of 20
`
`US 9,017,721 B2
`
`SUO!1B!JB/\
`
`“ “ “ “
`
`\—LOLOLOLOl-DLOLDLOLDLOLD
`
`\— or
`L0
`\— L0
`or
`\— Lo
`<i- N
`_
`®CDl\l\LOLDLO<l'(V)03
`Lur1()z>°/080000
`_
`rxmcow
`Ino'>oor\x—
`:3
`<r
`uJHOL>%q-
`l\l\l\l\
`®<r<">(")<")\—
`
`oo
`
`ParticleSize
`
`wrt o9'o> %
`
`Lurt oz'o> %
`
`'SU!l.U) 3UJ!J_
`
`Lo
`
`S 8 DIflfiflfiIEEEMIWEEIEEI“0.333
`
`F I\ w
`
`I\
`l\
`
`CD
`CO
`\— LO
`('3
`0')
`\— LO
`F LO w
`\— <l'
`L0
`C0
`<1’
`I
`
`TL
`
`O
`
`CO
`
`V <
`
`l'
`l\
`C")
`K)
`N
`
`E(
`
`'3
`(13
`O")
`l\
`0
`N
`L0
`
`T N N T N
`
`T:
`
`3
`
`co
`co
`
`o"
`
`
`
`
`
`
`
`
`
`ActivematerialPrimaryMatrixSurfactant#1Surfactant#2
`
`M/M %
`IIIIIIIIIIII 3 I 1
`
`0.
`
`WM% I
`LO
`LO
`LO
`LO
`LO
`LO
`LO
`LO
`LO
`LO
`<6>SSew;;::33§:2:2 0"" --
`
`Figure1F
`
`°°
`an
`(n < _I
`" K
`<0
`SLUBNSQE’
`53$:/)ooLu
`D
`|— an
`o.
`0.
`no
`a.
`|— D (0 U) 0
`co
`EQQEE fig Q
`co <r
`<r
`wr
`<r ,,
`<r
`<r
`Lo
`
`<l' N N N N N NN N N N N <l'
`
`SUJBNOOOOOOOOOOOOO
`
`Efififififififififi
`II III
`
`FLDLOLDLOLDl0LDLDLOLOLDF\—
`
`c>'L\i<\iL\i<\ic\i<\ic\i<\ic\ic\ic\io'o'o""'
`2 z
`
`.
`
`E
`O 0 O O
`[I
`UJ
`u.
`(D I
`an
`I— 3 >
`X >- N <::
`0
`-2
`°N9'dweSEEE
`
`Page 8
`
`Page 8
`
`
`
`U.S. Patent
`
`Apr. 28,2015
`
`Sheet 7 of 20
`
`US 9,017,721 B2
`
`SUOi1BiJB/\
`
`\—\—\—LOLOLOLOLO
`
`ooommrxrx
`
`N
`
`I\
`
`rxrx
`
`ix
`
`o<r
`U_m-
`°<r
`<1-I\\—N
`8r\N,\\—r
`<r
`03>/olx
`Eco
`oooomoo
`_Lom ©l\
`cm
`-
`O
`r\r\©°r\Lo°0ooLo<roo
`com
`W°~%EHEEfiHIIemw+mww~$w~
`-
`LoLo°cv>
`<1-oo
`com
`WWW
`II fiiififlfififififllfifll
`79 95
`NN
`<rl\
`LO©®
`no
`rxm N<rN©Nx-
`<1-<r
`k
`wri 0s:'0> °
`72
`84
`63
`
`$
`
`T
`
`w
`
`LO
`(‘'3
`
`wri 0z'0> %
`
`E 1 G|8 D
`
`('Su!w)ew!1
`
`017357 015965
`
`LOO<l'\—O‘_C")®LOLO
`\—\—oocv><r
`<r<rl\c*)
`
`022943 0553
`
`cm
`NO
`oo
`ooN
`&1‘..®.fi
`.......oLO.
`O
`NO
`0
`
`15 20
`
`20 20
`
`M/M0/0 N
`
`0')
`co
`
`Iumammummmmnllnllmnmmml
`
`Figure1G
`
`ParticleSize
`
`9:
`
`E.
`
`59
`8'1:5
`<0
`
`EE.
`
`59
`8*1:5
`<0
`
`
`
`PrimaryMatrix
`
`
`
`Activematerial
`
`
`
`
`
`WEEK-Eflfiflfimflfifllfl0-319-HEgflfim-@EE!L—-L—IE@flflnDMsosmsosEEMEE-WE£fl®mlL—Im@EEEE sos
`01 SDS01Iililliiiifi-—®%Efl®fl--—E@
`
`6 ssew
`
`SUJB
`
`/v\//v\ 0/
`
`(6) ssew
`
`BLUE
`
`3 $2
`
`E
`
`SUJB
`
`A/A 0/
`
`/v\//v\ 0/0
`
`(6) ssew -
`
`\—
`
`01 01
`
`\-
`
`L9“?mm
`oooo
`
`445
`
`445
`
`445 C445
`II
`|lII SOR LA
`
`(6) ssew -
`
`10 10
`
`10 10
`5 5
`.......ga222:22::2
`0 0
`05 05
`o'o'c>'c>'c>'c>c>c>ooo
`
`eLueN
`
`'oN eidwes
`
`CEL
`
`CYA
`
`BE HHHHEHHH!!!
`
`(DCDOOOOOOOOO
`
`(DI-D>
`
`><>-N<mo
`
`Page 9
`
`Page 9
`
`
`
`U.S. Patent
`
`Apr. 28,2015
`
`Sheet 8 of 20
`
`US 9,017,721 B2
`
`
`
`
`
`Eraiensity[arbitraryunitgj
`
`6
`
`8
`
`10
`
`12
`
`14
`
`15
`
`Défiraciian Angie {2}
`
`Figure 1H
`
`Page 10
`
`Page 10
`
`
`
`U.S. Patent
`
`Apr. 28,2015
`
`Sheet 9 of 20
`
`US 9,017,721 B2
`
`suoueue
`
`suoneue
`
`
`
`
`
`®N_mm_o_tmmSKEfiomtswx_:m_>_>._mE_._n__m:9mE®>=O<
`
`
`
`
`
`www.
`
`lmEEEEEfiaI"E§EIEEE
`.|_%WN%WN%%WN
`MMMmmmmmw
`)m)M)Am)e>>>.WMWm_c.L.0..
`
`
`
`
`IIEEEEE§aHaEEEIEEEm-
`
`IIEEEEE§fiHEEEEEIEEnEH
`
`IEEEEEEEEEEaEEEIEEEH—
`
`IHEEEEEEEIIIEEEIEEEH
`
`Ilfififlfiflgufiflaaggfiaagl
`
`<N9:9“.
`
`'oN e|du.1e<3
`
`/:\
`
`
`
`
`
`
`
`mumw_o_tmn_ x_:m_>_>.mE:n__m__m_.mEm>=o<
`
`(%) P|9|
`
`A.AGN
`.0000%W%WN%WN
`
`
`
`.Ix(\/.\>>>.WmW%Wm009)WWW.n.n.n
`
`
`
`.
`
`www
`
`IIEEEEEEEEEEEHEEEH
`
`IIEEEEEEEEEEEHEEEH
`
`IIEEEEEEEEEEEEEHEH
`
`IIEEEEEEEEEEEEEHEH
`
`IIEEEEEEEEEEEEEHEH
`
`<m9:9“.
`
`0N e|du1es
`
`Page 11
`
`Page 11
`
`
`
`U.S. Patent
`
`Apr. 28,2015
`
`Sheet 10 of 20
`
`US 9,017,721 B2
`
`<m2:9”.
`
`\)%/\
`
`.IA.5D.
`
`
`EE%%>>ZLwmif
`EB%%
`
`>.09AHw
`
`EE
`EE
`
`EE
`EE
`
`BEEE5
`EE
`Efi
`E5
`
`EE
`
`Luri ()3 (]>
`
`..Mw
`
`a
`
`90
`
`m
`
`«No
`
`_,©N.o
`
`£3
`
`Ewe
`
`$2.
`
`LO
`LO
`F.
`O
`
`EEEofOEEz<_>_3.0,.
`
`'oN S|dUJBS
`
`Page 12
`
`suoneue
`
`>Z
`
`000\la/i>.0.
`
`.0
`
`.nH.www
`.0..G0c._.nx)
`fixmmfix®
`
`lfiafififlfififilllfiflfififigfiaga
`.Wm)W)MW)
`o%WNoWN%WN%%WNSM2MAM
`
`Emm_o_:$
`
`
`
`52.5Ilfififlflflgfilllflflfififiaflaagfl
`
`IEEEEEEEEIIIIIIEEEIEEEH
`
`IHEHEEEEEIIIIIIEEEIEEEH
`
`IHEEEEflEEEEEI'IEEgIEEEH—
`
`Ififlflflfiflgfilllfiflfigaaaagfl
`
`IEEEEEEEEEEEEEEEEIEEEH
`
`
`
`wN_mw_o_tmn_( sfcfiomtzwxEm_>_bmE__n__m__BmEw>=o<
`
`
`
`
`
`
`
`Page 12
`
`
`
`U.S. Patent
`
`Apr. 28,2015
`
`Sheet 11 of 20
`
`US 9,017,721 B2
`
`S
`
`PA.Wm.D.m.m
`
`HE
`
`HEMEMI
`
`IEIEIEIEIEIEIEIEMEMEME
`
`HE
`
`HIHI
`
`
`
`IEEIEE
`
`cn
`I\
`
`<09:9“.
`
`
`
`mm:EIIIEEEHIEEEEIEEEE
`
`
`
`33EIIIEEEEIEEEIEEEE
`
`Page 13
`
`IEEW%%
`
`IEE
`
`IEE
`
`IEE
`
`IEE
`
`IEE
`
`IEE
`
`IEE
`
`IEE
`
`IEE
`
`IEE
`
`IEE
`
`IEE
`
`IEE
`
`IEE
`
`IEE
`
`C\l\—oo\—L0
`ooo7oo<o°0
`<1-Ln
`ox-
`LOl\
`LON
`oLoooooo'>
`coLo<rmLo
`
`m
`
`.9MMuww
`
`mumm._o_:mn_
`
`LO
`l\
`
`U") 9'0 > %
`
`W“ 09'0> %
`
`W“ 0Z'0> %
`
`0
`
`<'S“!w> awEEEE
`
`to
`
`WEEEHIEEEIEEEE
`
`No-.0II
`
`3IEEHIEEEEIEEEE
`
`mIIIIIEEEEEIEEEE
`
`
`
`3;IIIEEEEEEEEEIEEEE
`
`Ix
`cnrxtoo
`co
`co
`Inoucnrx
`<r
`c\|x—
`<—<*>oo
`<00)
`rxrx
`<rr~<r
`ooLo
`\—LOLD<l'C0<l'l\CVDO
`CO
`c~'>Loco<o<o<r<rLoLo
`(\l(\l
`_,
`mom
`mv
`_,
`_,
`O(\l
`N
`E3
`C\lC\l
`(\lC\l
`
`.1..0.
`GOO QC)
`
`GO
`
`9.
`m
`
`,0-.II
`
`,0as
`
`,0-_.II.II.II
`
`.II.II
`
`5
`C
`
`,.-,-1II
`
`
`
` %pN.%wNowNowNoow,.N.MwmeMMMMwllllA!MeM)M)M)M)eW4x4xW wkEflomtsmEEfiomtzm
`
`
`
`xEm_>_bmE__n__m_.9mEw>=o<
`
`'oN e|du1es
`
`IIIIIIIIIIII
`II
`
`IIIHEEEEIEEEH
`
`IIHIEEEIEEEE
`
`IIEEEEEIEEEE
`
`KIIEEEEEIEEEE
`IIIIIEEEIEHEE
`
`IIIEEEEEIEEEE
`
`IIIHEEEEEEEEE
`
`IIIIIIEEEIEEEE
`
`IIIEEEEEIEEEE
`
`IIIHEEEEIEEEE
`
`IIIHEEEEIEEEH
`
`HHEHIEEEIEEEE
`
`Page 13
`
`
`
`U.S. Patent
`
`Apr. 28, 2015
`
`Sheet 12 of 20
`
`US 9,017,721 B2
`
`0I
`
`DHI
`“B
`IIIIIIIIIIII
`O O
`<r O Ix
`Lo
`-
`l\
`L””°Z>°/°9 °°
`°°
`N <r a <1-
`-
`Lo
`0 O
`O
`O
`«>
`u"‘0L>°/°8 3 <=“o 9
`<» ~ w
`-
`oo
`Q3 9 O
`0')
`cv:
`C’
`l\
`Lo
`<r
`on N co
`G <1-
`
`ParticleSize
`
`-
`
`LO
`
`<l'
`
`03
`
`L0
`
`-
`(D
`O |\
`@ C\l C) N
`O‘) V V’
`CV
`'10
`w“ oz 0> %EEEEE
`'\
`'\
`O7
`(9)
`VI‘
`03 Q.
`00 $ VI‘
`CV)
`to (\I
`CV
`61
`‘_
`C7}
`1-
`i\
`‘—.
`51' 9 *—_ § 3 ‘—_ 9 C 9 3 N 59 9 CC?
`0? 3 '3 R1
`0 d d O o d 0 d d d d 0 d d 0 D d d d
`3 3 3 $ LO 3 Lt.) $ 3 3 3 U3
`3 3 3 3 3 3
`
`Lur1(g'0)c|
`
`-
`
`_ —————————————Z————
`R;
`(6) ssel/\I—————————————2————
`—————————————2————
`LO
`LO
`LO
`LO
`N IIIIIIIZIIII
`l\
`LO
`LO
`LO
`LO
`5 '5
`".
`".
`I‘
`
`(6) ssew <0
`
`Figure6B
`
`Page 14
`
`rsaoflflzoo11
`
`L
`
`fiflfifllfififimIaaammlmmt=n-1—-
`AGPRO3010LAC26789
`
`“
`
`EWEIEIEEE
`
`0000
`gi_uuJLu|.u
`_l_l_l_l
`‘_C\lC’)
`1
`
`FF
`
`L°...unto
`Lo
`'m"‘S_>
`«$65
`CDIDOOCOCD
`CDQDOOGDCD
`V1???"
`D_D_D_D.D_
`
`CV3
`
`oo
`
`eLueNr\
`E
`
`0
`VLo.u=.<==>.oo.c'>.r'>.°=>.m.L0.c>..
`(6)ssewN::8&°88‘s::2
`“
`<"><"J<"'JCV3C“)<“'><“'>C")CV3C“)
`
`IIIIIIIIIII
`5 5
`OD
`10
`
`
`
`amenflmflEWEMWEmmm5HEWawnEWE1EME1EmaEWEEMMEEIMAN315
`
`(6) ssew
`
`'oN eidwes
`
`Surfactant#
`
`
`
`
`
`PrimaryMatrixSurfactant#1
`
`
`
`Activematerial
`
`Page 14
`
`
`
`U.S. Patent
`
`Apr. 28,2015
`
`Sheet 13 of 20
`
`US 9,017,721 B2
`
`EEIEEEEEEEw..0wT
`ESEEE
`(\l
`‘E
`co
`\l7
`
`V®
`
`®(
`
`N
`
`mumm_o_tmn_
`
`EEEEE
`HE
`EEHEH
`HE
`
`gfi--IIIIIIEEEIQEEHm%N%wN%wN%wN%%wN.oMmmwmmmmW@)m)emHM)M)Am)amwwwww
`
`E3--ENEEfiEEEIE§EE
`
`Ea--IIIIIIEEEIEEEE
`
`EEE--EHEEEEEEIEEEE
`
`fig!-IIIEEEEEEEEEEE
`
`'oN e|dLue3
`
`EEEH--IIIIIIEEEEEEEE
`
`EEEH--IIIEEEEEEEEEEE
`
`EEEE--IIIIIIEEEEEEEE
`
`EEEEE--IIIEEEEEIEEEE
`
`EEEEE--IIIEEEEEEIEEEE
`
`ow9:9“.
`
`Page 15
`
`
`
`
`
`(%NfcmgomtsmEficfiomtsmx_:m_>_\CmE_._n__m_§.mEm>_..o<
`
`
`
`
`
`
`
`Page 15
`
`
`
`U.S. Patent
`
`Apr. 28,2015
`
`Sheet 14 of 20
`
`US 9,017,721 B2
`
`suoneue
`
`(%) Duel
`
`
`
`
`
`
`
`mN_wm_o_.._m.n_EEm9:_m_n_mumEfiomtswEEfiomtzwxEm_>_>.=mE_._n__m_§m.Em>=o<
`
`
`
`
`
`
`
`
`
`SUILU) eLu|
`M/M
`
`5) sse
`
`www
`
`.n.n.flw.(\(\(\(\(\(\
`
`WCEEEEEEE-IIIIIIIIEEEEEEIEEEH
`
`.oxG,:_%wN%wN%wN%wN%wNoowN
`>>>.0.mmwMmemmMm._6.L.0..m._\GWSWWW3A9
`
`to
`
`HIEEEEEEE-IIIIIIIIIIIEEEIEEEH
`
`HIEHEEEEE-'I"'II'EEaEEEIEEEH
`
`HIEEEEEEE-IIEHEEEEEEEEEEIEEEE
`
`HIEEEEEEE-'I"'EEEEEaEEEIEEEH
`
`HIHEEEEEE-IIIIIIIIEEEEQEIEEEH
`
`HEan-EHEEE-IIIIIIIIIIIEHEIEHEH
`
`HEE386Ea-'I"'EEEEEEEaEIEHEH
`
`H3EEEEEEEaE_EHEEEEEEEEEfiEIEEE-
`
`HIEHEEEH-'I"'IHEEHaEEEflE—fiEH
`
`HIEEEEEEE-llllflaaflaafifigflaagg
`
`HIEEEEEEE-llllflafiflaafiagflanfigi
`
`HIEEEEEEE-Illlflaaflaafifigfiaagfi
`
`HEIIIIIIEMEEIIIEEEIIIIIIIEEEE
`
`EHEEEEflea-IIIIIEHEEHQEEEEEEEH
`
`<n053
`
`'oN e|du1e3
`
`Page 16
`
`Page 16
`
`
`
`U.S. Patent
`
`Apr. 28,2015
`
`Sheet 15 of 20
`
`US 9,017,721 B2
`
`
`
`
`
`wN_mm_o_tmn_( mtEmfimtsmSmEm..omt:mx_._..m_>_>._mE_._n__m_._9mEm>_..o<
`
`
`
`
`
`
`
`suoneue/\
`(%) P|9|A
`
`www
`
`0EEfiEEE€I"II.HEaEEEIEEEE
`
`.000).%wN%0w.0N.%wN%wN%%0w.
`.n\)55555w.(((((
`>>>.0MMsMMAM
`009
`z.L.o..@W)wwww)W)Mwm
`
`'oN e|dLueg
`
`0EEEfifiEEHI"EflEHEEaEEIEEEn-
`
`EEEEEEEEHIIIEEEHEEEEEIEEEH
`
`IEfiEfiEfiEHEEEII.Ea&aaEIE§EH—
`
`IEEEEEEEHEEIIIIIIQEEIEEEH
`
`IEEEEEEEHEEEIIIHEEQEIEQEH
`
`IEEEEEEEHI.'II.H§&EEIEEEH
`
`IEEEEEEEHI"II.Eaaa§IEEEE
`
`EEEEEEEEHIIIEEEEEEQEEEEEEI
`
`EEEEEEEEHIIIIIIHEEEEEIEEEH
`
`IEEEEEflEHI.'II.Ha&aEEIEEEH
`
`IEEEEEEEEI.'E&EHag@§EEE§El
`
`IEEEEEfiEHEaEEEEHaEEEEfi§EE
`
`
`
`EEEEEEEEHI.'II.Ha&aEEIEEEEEEEEEEEEEIIIIIIEEEEEEIEEEHEEEEEEEEEIIIIIIEEEEEEIEEEE
`
`
`
`<w9:9“.
`
`Page 17
`
`Page 17
`
`
`
`U.S. Patent
`
`Apr. 28,2015
`
`Sheet 16 of 20
`
`US 9,017,721 B2
`
`suoneue/\
`
`(%)mmA
`
`IIII
`.0
`
`HEE
`
`HEEEEEEEIIIE-EEEEEEEEEIEE
`
`HEEEEEEEEIIIE-EEHEEEEEHEH
`
`EEIEEEEEEEIIIEEEEEEEEEHHEH
`
`HEIEEEEEEEIIIEEEEHEEEEHHEH
`
`HEEEEEEEEEIIIIIIIEEHEEEEEE
`
`HEIEEHEEEEIIIIIIIIIEEEEEEH
`
`
`
`IEEEEEEEEEIIIIIIEHHEEEHEHE-HIEEEEEEEHEIIIIIIIIIHEEEEHEE
`
`IEEEEEEEEEIIIIIIIIIHEEHEHEH
`
`IEIEEEEEEEIIIIIIIIIHEEEEEH
`
`HEEEEEEEEEIIIIIIEHHEEEEEH
`
`EIIIIIIIIEIIIIIIIIIEEHEEEEE
`
`HEIEHEEEEEIIIIIIHHHEHEEEEE
`
`EEIHEEEEEEEEEIIIHHHEEEEEHEH
`
`EEIEEEEEEEIIIIIIEHHEHEEHEH
`
`EEII§IEE§E"III'flaEnE§EEEEH
`
`HEIEEEEEEEIIIIIIEEHQEEEEEH
`
`HalEEEEEEEEEEIIIEHEEHEEHHEH
`
`<m9:9“.
`
`(\W.
`
`m_o_tmn_
`
`AH.
`
`(6) ssew
`
`(SUILLI) 3uJ|J_EEEEIIIEEEEHEEEHHEE
`
`
`
`
`
` mEcEomt:mSfcfiomtzmx_.zm_>_>._mE_._n__m_._9mEm>=u<
`%W%W%WN0WWMwMwMwMeMaM3m
`
`‘ON e|du.1e3
`
`Page18
`
`Page 18
`
`
`
`U.S. Patent
`
`Apr. 28,2015
`
`Sheet 17 of 20
`
`US 9,017,721 B2
`
`IIIIIIIII
`IIIIIIIIIIIIIIIIIIE
`IIIIIIIIIIIIIIIIIIII
`-
`Ix
`Ix
`«3
`co
`«3
`Ix
`‘3
`
`LO
`
`Ix
`
`Ix
`
`-
`
`-
`
`Ix
`
`co
`
`LO
`
`cn
`
`to
`
`oo
`
`oo
`
`LO
`
`‘3
`
`O
`
`-
`cm
`o
`<r
`Ix o co
`LO o o Lo
`N <1-
`LU” 09 0> %EE
`-
`o'>©loLo
`O3COVI\VC*)©l\
`l\c‘OLOVO3
`W‘ 03 0> %
`
`.
`r1
`W (9 0)C|
`
`B
`
`“
`
`\— \— \— \— \— \— \— \— \-
`LD
`LO
`LO
`LO
`
`LO
`
`LO
`
`LO
`
`LO
`
`ParticleSize
`
`.
`
`E.
`
`
`
`
`
`PrimaryMatrixSurfactant#1
`
`
`
`Activematerial
`
`CD ®
`(‘'3 © (‘'3 ® I\ O O ‘D \— ® L0 V ® 0')
`C) ® (V
`(‘'3
`(V
`® I\
`CD ® ® C ® (‘'3 0 ® ® O ® 5) ® ® LO
`‘—.
`‘—.
`".
`‘—. V.
`*'. N.
`<">.
`°'>. W.
`0'3.
`0'3.
`<0.
`0! V. N ‘—.
`‘—.
`‘—.
`O o ‘ o o o O O O o o o c: o O O o o c)
`c)
`CO
`CO G CO
`CO
`9 L0 C)
`LO
`-
`< SW) aw EEEEEEEEE
`'-°.L°.‘9.
`M/M70555
`IIIIIIIIIIIIIIII
`IIIIIIIIIIIIIIII
`=n:
`IIIIIIIIII
`IIIIIIIIII °
`53
`8H:D
`Figure
`D. D. D.
`D.
`0.
`eweN
`%>%%>%>>>
`to
`D. D. D. D. D. D. D. D. D.
`
`599629SDS95
`
`.
`
`99629SDS955
`
`.
`
`599629SDS955
`
`.
`
`599629SDS955
`
`.
`
`99629SDS955
`
`.
`
`599629SDS955
`
`.
`
`co
`
`to
`
`629SD 9SD
`
`.
`
`co U)
`(D co
`to
`gamma
`m to U)
`o)
`co
`
`. Q "1
`
`"1
`
`5".
`
`V’.
`
`® ® G V V V V
`
`V V V V V V
`
`V V LO
`
`LO
`
`1-D
`
`L0
`
`on
`to
`co
`co
`co
`(0
`eweyqoooooo
`(0
`co
`co
`en
`en
`co
`
`L0.
`
`L‘?
`
`‘D.
`
`LO
`
`O O
`
`84
`
`ND13013MWEEEEEWE15
`
`9 B
`
`LAC645
`LAC645
`eweI. I §
`§§§3‘533‘
`o o E 2 g E 2 E Z Z Z 0 0 o o
`o
`15015
`ND13013
`ND13013
`- - - E E 2
`—
`UJ
`LIJ
`LIJ
`UJ
`0 E
`_l
`_l
`_l
`_l
`V
`'°N9'dwe8 E
`
`Page 19
`
`Page 19
`
`
`
`U.S. Patent
`
`Apr. 28,2015
`
`Sheet 18 of 20
`
`US 9,017,721 B2
`
`suoneue
`
`(
`
`
`
`mumm_o_:$EEsomtsmxEm_>_>585
`
`
`
`_®_._®__®C._m>__.o<
`
`.n.n.nwmmm
`
`009
`
`>Z
`
`>>L0
`
`IIEEEEEEEEEElififlflflfififigfi
`0000\/%WMw.(
`
`
`
`'IEEEEEEEEEfi
`
`IIEEEEEEIII
`
`Iafiflfifigggfi
`
`IEEEEEEEEEE
`
`<89%:
`
`mmW
`
`M\)
`
`RU(\
`
`EEEEEE
`EgEEEQ
`
`Page20
`
`Page 20
`
`
`
`U.S. Patent
`
`Apr. 28,2015
`
`Sheet 19 of 20
`
`US 9,017,721 B2
`
`
`
`
`
`
`
`
`
`®N_m®_O__tmn___Cm._®w_—C_m_Dmum_—Cm__Om._.=..mN3.“EflomtzmEfiomtsmx_.:®_>_\CmE_._n__m_.QmE®>___Q<
`
`
`
`
`
`
`
`
`
`
`
`suoneue/\
`
`>Z0.nw
`
`SUIUJ) eLuu_
`
`.A.oooooG%WN%WN%WN%W%N%%WN\).BBBBB>.MSMSwMMSMMMw...
`..M\)M\)9MM\)MM9Mww(w((ww.
`
`'oN e|du1es
`
`re
`
`lawEEEEflfiEI"IIIEHEEHfi§EEEEEEH
`
`IIEEEEEEEIIIIIIEEEEHfifiagfififiamn
`
`IIEEEEEEEIIIIIIEEEEHfifiggfifiaga
`
`lgEEEEEEQIIIIIIEEEEHEEEEEEEEH
`
`IEEEEEEEEIIIIIIIIIEHEEEEQEEEH
`
`EQEEEEEEEEEEEHEEHEEHfififigfifiaal
`
`IEIIIIIIEEEEHEEEHEEHfififigfifiagfi
`
`IEIIIIIIEEEEIIIEHEEHfififigfifiggfl
`
`.§EEEEEEEIIIIIIEHEEHfififigfifiag-u
`
`IQEEEEEEEIIIEEEEHEEHEEEEEEEEH
`
`IEEEEEEEEIIIIIIIIIIIIEEEEEEEH
`
`EaEEEEEEEEEEIIIIIIIIIEEEIEEEH
`
`EHEEEEEEEEEEIIIIIIIIIEEEIEEEE
`
`<:925
`
`Page 21
`
`Page 21
`
`
`
`U.S. Patent
`
`Apr. 28,2015
`
`Sheet 20 of 20
`
`US 9,017,721 B2
`
`
`
`
`
`
`
`mN_mm_o_tmn_Nuficfiomtsmrfcfiomtsmx_:m_>_>._mE_._n__m_§.mEm>_..o<
`
`
`
`
`
`
`
`/|\
`
`suoneue
`
`A.A
`
`0.nw
`
`>Z
`
`>L0Inw
`
`%oom.%wN%wN%wN%wpN.
`
`....()M)M)M)M)eMmwwwww.
`>.0MMMMw09llll
`
`'oNewwe3
`
`.m
`
`IEEEEEEHEEEEEEEEEEEEE
`
`EIEEEEEEIIIIIIIIIIIIEH
`
`Ifi§EEEE§aI"EEfiE§EEEH
`
`EIEEEEEEIIIIIIIIIIIIEH
`
`IEEEEEEEHIIIIIIHEEEEE
`
`IEEEEEEEHIIIIIIEEEEEE
`
`EIEEEEEEIIIIIIIIIIIIEH
`
`EIEEEEEEIIIIIIIIIIIIEE
`
`IEEEEEEEEEEQEEEEEEEEI
`
`IEEEEEEEEEHEEEfiEEEEEEH
`
`EIEEEEEEIIIIIIIIIIIIEE
`
`EIEEEEEEIIIIIIIIIIIIEH
`
`<m_9:9“.
`
`Page22
`
`Page 22
`
`
`
`1
`FORMULATION OF DICLOFENAC
`
`RELATED APPLICATIONS
`
`US 9,017,721 B2
`
`2
`
`This application is a continuation and claims priority to
`U.S. application Ser. No. 14/167,652, filed Jan. 29, 2014,
`which is a continuation of U.S. application Ser. No. 13/266,
`122, filed Feb. 16, 2012, which is a U.S. national stage under
`35 USC §371 of International Application Number PCT/
`AU2010/000471, filed on 23 Apr. 2010, which claims priority
`to AU Application No. 2009901748, filed on 24 Apr. 2009 and
`U.S. Application No. 61/172,291, filed on 24 Apr. 2009, the
`entire contents of which applications is hereby incorporated
`by reference.
`
`FIELD OF THE INVENTION
`
`The present invention relates to methods for producing
`particles of diclofenac using dry milling processes as well as
`compositions comprising diclofenac, medicaments produced
`using diclofenac in particulate form and/or compositions, and
`to methods of treatment of an animal, including man, using a
`therapeutically effective amount of diclofenac administered
`by way of said medicaments.
`
`BACKGROUND
`
`Poorbioavailability is a significant problem encountered in
`the development of compositions in the therapeutic, cos-
`metic, agricultural and food industries, particularly those
`materials containing a biologically active material that is
`poorly soluble in water at physiological pH. An active mate-
`rial’s bioavailability is the degree to which the active material
`becomes available to the target tissue in the body or other
`medium after systemic administration through, for example,
`oral or intravenous means. Many factors affect bioavailabil-
`ity, including the form of dosage and the solubility and dis-
`solution rate of the active material.
`
`In therapeutic applications, poorly and slowly water-
`soluble materials tend to be eliminated from the gastrointes-
`tinal tract before being absorbed into the circulation. In addi-
`tion, poorly soluble active agents tend to be disfavored or even
`unsafe for intravenous administration due to the risk of par-
`ticles of agent blocking blood flow through capillaries.
`It is known that the rate of dissolution of a particulate drug
`will
`increase with increasing surface area. One way of
`increasing surface area is decreasing particle size. Conse-
`quently, methods ofmaking finely divided or sized drugs have
`been studied with a view to controlling the size and size range
`of drug particles for pharmaceutical compositions.
`For example, dry milling techniques have been used to
`reduce particle size and hence influence drug absorption.
`However, in conventional dry milling the limit of fineness is
`reached generally in the region of about 100 microns (100,
`000 nm), at which point material cakes on the milling cham-
`ber and prevents any further diminution ofparticle size. Alter-
`natively, wet grinding may be employed to reduce particle
`size, but flocculation restricts the lower particle size limit to
`approximately 10 microns (10,000 nm). The wet milling pro-
`cess, however, is prone to contamination, thereby leading to a
`bias in the pharmaceutical art against wet milling. Another
`alternative milling technique, commercial airj et milling, has
`provided particles ranging in average size from as low as
`about 1 to about 50 microns (1,000-50,000 nm).
`There are several approaches currently used to formulate
`poorly soluble active agents. One approach is to prepare the
`active agent as a soluble salt. Where this approach cannot be
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`employed, alternate (usually physical) approaches are
`employed to improve the solubility of the active agent. Alter-
`nate approaches generally subject the active agent to physical
`conditions that change the agent’s physical and or chemical
`properties to improve its solubility. These include process
`technologies such as micromzation, modification ofcrystal or
`polymorphic structure, development of oil based solutions,
`use of co-solvents, surface stabilizers or complexing agents,
`micro-emulsions, supercritical fluid and production of solid
`dispersions or solutions. More than one of these processes
`may be used in combination to improve formulation of a
`particular therapeutic material. Many of these approaches
`commonly convert a drug into an amorphous state, which
`generally leads to a higher dissolution rate. However, formu-
`lation approaches that result in the production of amorphous
`material are not common in commercial formulations due to
`
`concerns relating to stability and the potential for material to
`re-crystallize.
`These techniques for preparing such pharmaceutical com-
`positions tend to be complex. By way of example, a principal
`technical difliculty encountered with emulsion polymeriza-
`tion is the removal of contaminants, such as unreacted mono-
`mers or initiators (which may have undesirable levels of
`toxicity), at the end of the manufacturing process.
`Another method of providing reduced particle size is the
`formation of pharmaceutical drug microcapsules, which
`techniques include micronizing, polymerisation and co-dis-
`persion. However, these techniques suffer from a number of
`disadvantages including at least the inability to produce suf-
`ficiently small particles such as those obtained by milling, and
`the presence of co-solvents and/or contaminants such as toxic
`monomers which are diflicult to remove, leading to expensive
`manufacturing processes.
`Over the last decade, intense scientific investigation has
`been carried out to improve the solubility of active agents by
`converting the agents to ultra fine powders by methods such
`as milling and grinding. These techniques may be used to
`increase the dissolution rate of a particulate solid by increas-
`ing the overall surface area and decreasing the mean particle
`size. U.S. Pat. No. 6,634,576 discloses examples of wet-
`milling a solid substrate, such as a pharrnaceutically active
`compound, to produce a “synergetic co-mixture”.
`International Patent Application PCT/AU2005/001977
`(Nanoparticle Composition(s) and Method for Synthesis
`Thereof) describes, inter alia, a method comprising the step of
`contacting a precursor compound with a co-reactant under
`mechanochemical synthesis conditions wherein a solid-state
`chemical reaction between the precursor compound and the
`co-reactant produces therapeutically active nanoparticles dis-
`persed in a carrier matrix. Mechanochemical synthesis, as
`discussed in International Patent Application PCT/AU2005/
`001977, refers to the use of mechanical energy to activate,
`initiate or promote a chemical reaction, a crystal structure
`transformation or a phase change in a material or a mixture of
`materials, for example by agitating a reaction mixture in the
`presence of a milling media to transfer mechanical energy to
`the reaction mixture, and includes without limitation “mecha-
`nochemical activation”, “mechanochemical processing”,
`“reactive milling”, and related processes.
`International Patent Application PCT/AU2007/000910
`(Methods for the preparation of biologically active com-
`pounds in nanoparticulate form) describes,
`inter alia, a
`method for dry milling raloxifene with lactose and NaCl
`which produced nanoparticulate raloxifene without signifi-
`cant aggregation problems.
`One limitation ofmany ofthe prior art processes is that they
`are not suitable for commercial scale milling. The present
`
`Page 23
`
`Page 23
`
`
`
`US 9,017,721 B2
`
`3
`invention provides methods for overcoming the problems
`identified by the prior art by providing a milling process
`which provides particles with increased surface area, yet can
`also be scaled up to a commercial scale.
`One example of a therapeutic area where this technology
`could be applied in is the area of acute pain management.
`Many pain medications such as diclofenac are commonly
`prescribed as pain relief for chronic pain. As a result they are
`commonly taken on a daily basis to maintain an effective
`therapeutic level. Diclofenac is a poorly water soluble drug so
`dissolution and absorbtion to the body is slow. So a method
`such as the present invention which provides for improved
`dissolution, will likely provide much faster absorption result-
`ing in a more rapid onset of the therapeutic effect. By using a
`method such as the present invention, which provides faster
`absorption, a drug such as diclofenac, could be used more
`readily to treat acute pain as well as chronic pain.
`Although the background to the present invention is dis-
`cussed in the context ofimproving the bioavailability ofmate-
`rials that are poorly or slowly water soluble, the applications
`ofthe methods ofthe present invention are not limited to such,
`as is evident from the following description of the invention.
`Further, although the background to the present invention
`is largely discussed in the context of improving the bioavail-
`ability of therapeutic or pharmaceutical compounds,
`the
`applications of the methods of the present invention are
`clearly not limited to such. For example, as is evident from the
`following description, applications of the methods of the
`present invention include but are not limited to: nutraceutical
`and nutritional compounds, complementary medicinal com-
`pounds, veterinary therapeutic applications and agricultural
`chemical applications, such as pesticide, fungicide or herbi-
`cide.
`
`Furthermore an application of the current invention would
`be to materials which contain a biologically active compound
`such as, but not limited to a therapeutic or pharmaceutical
`compound, a nutraceutical or nutrient, a complementary
`medicinal product such as active components in plant or other
`naturally occurring material, a veterinary therapeutic com-
`pound or an agricultural compound such as a pesticide, fun-
`gicide or herbicide. Specific examples would be the spice
`turmeric that contains the active compound curcumin, or flax
`seed that contains the nutrient ALA an omega 3 fatty acid. As
`these specific examples indicate this invention could be
`applied to, but not limited to, a range of natural products such
`as seeds, cocoa and cocoa solids, coffee, herbs, spices, other
`plant materials or food materials that contain a biologically
`active compound. The application of this invention to these
`types of materials would enable greater availability of the
`active compound in the materials when used in the relevant
`application. For example where material subject to this inven-
`tion is orally ingested the active would be more bioavailable.
`
`SUMMARY OF THE INVENTION
`
`In one aspect the present invention is directed to the unex-
`pected finding that particles of a biologically active material
`can be produced by dry milling processes at commercial
`scale. In one surprising aspect the particle size produced by
`the process is equal to or less than 2000 nm. In another
`surprising aspect the particle size produced by the process is
`equal to or less than 1000 nm. In another surprising aspect the
`crystallinity of the active material is unchanged or not sub-
`stantially changed. In a preferred embodiment the present
`invention is directed to the unexpected finding that particles
`of diclofenac can be produced by dry milling processes at
`commercial scale.
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`4
`
`Thus in a first aspect the invention comprises a method
`producing a composition, comprising the steps of dry milling
`a solid biologically active material and a millable grinding
`matrix in a mill comprising a plurality of milling bodies, for
`a time period sufficient to produce particles of the biologi-
`cally active material dispersed in an at least partially milled
`grinding material.
`In one preferred embodiment, the average particle size,
`determined on a particle number basis, is equal to or less than
`a size selected from the group 2000 nm, 1900 nm, 1800 nm,
`1700 nm, 1600 nm, 1500 nm, 1400 nm, 1300 nm, 1200 nm,
`1100 nm, 1000 nm, 900 nm, 800 nm, 700 nm, 600 nm, 500
`nm, 400 nm, 300 nm, 200 nm and 100 nm. Preferably, the
`average particle size is equal to or greater than 25 nm.
`In another preferred embodiment, the particles have a
`median particle size, determined on a particle volume basis,
`equal or less than a size selected from the group 2000 nm,
`1900 nm, 1800 nm, 1700 nm, 1600 nm, 1500 nm, 1400 nm,
`1300 nm, 1200 nm, 1100 nm, 1000 nm, 900 nm, 800 nm, 700
`nm, 600 nm, 500 nm, 400 nm, 300 nm, 200 nm and 100 nm.
`Preferably, the median particle size is equal to or greater than
`25 nm. Preferably, the percentage of particles, on a particle
`volume basis, is selected from the group consisting of: 50%,
`60%, 70%, 80%, 90%, 95% and 100% less than 2000 nm
`(%<2000 nm). Preferably, the percentage of particles, on a
`particle volume basis, is selected from the group consisting
`of: 50%, 60%, 70%, 80%, 90%, 95% and 100% less than
`1000 nm (%<1000 nm). Preferably, the percentage of par-
`ticles, on a particle volume basis, is selected from the group
`consisting of: 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%,
`80%, 90%, 95% and 100% less than 500 nm (%<500 nm).
`Preferably, the percentage of particles, on a particle volume
`basis, is selected from the group consisting of: 0%, 10%,
`20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% and 100%
`less than 300 nm (%<300 nm). Preferably, the percentage of
`particles, on a particle volume basis,
`is selected from the
`group consisting of: 0%, 10%, 20%, 30%, 40%, 50%, 60%,
`70%, 80%, 90%, 95% and 100% less than 200 nm (%<200
`nm). Preferably, the Dx of the particle size distribution, as
`measured on a particle volume basis, is selected from the
`group consisting of less than or equal to 10,000 nm, 5000 nm,
`3000 nm, 2000 nm, 1900 nm, 1800 nm, 1700 nm, 1600 nm,
`1500 nm, 1400 nm, 1300 nm, 1200 nm, 1100 nm, 1000 nm,
`900 nm, 800 nm, 700 nm, 600 nm, 500 nm, 400 nm, 300 nm,
`200 nm, and 100 nm; wherein x is greater than or equal to 90.
`In another preferred embodiment